Q4 EPS Forecast for Hims & Hers Health Reduced by Analyst

Hims & Hers Health, Inc. (NYSE:HIMS) – Analysts at Leerink Partnrs reduced their Q4 2025 earnings per share estimates for Hims & Hers Health in a report released on Tuesday, August 5th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $0.11 per share for the quarter, down from their prior forecast of $0.17. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.29 per share.

Several other equities analysts have also recently weighed in on HIMS. UBS Group set a $30.00 price target on shares of Hims & Hers Health in a research report on Monday, June 23rd. Piper Sandler restated a “neutral” rating and issued a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Wall Street Zen cut Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday. Finally, Morgan Stanley restated an “equal weight” rating and set a $40.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $39.83.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $51.30 on Wednesday. The firm has a market capitalization of $11.48 billion, a P/E ratio of 64.12, a P/E/G ratio of 2.06 and a beta of 2.08. The firm’s 50-day moving average price is $53.79 and its 200-day moving average price is $44.63. The company has a current ratio of 4.98, a quick ratio of 1.32 and a debt-to-equity ratio of 1.72. Hims & Hers Health has a 1-year low of $13.47 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%. The business’s revenue was up 72.6% on a year-over-year basis. During the same period last year, the business posted $0.06 earnings per share.

Insider Transactions at Hims & Hers Health

In other news, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction on Monday, June 16th. The shares were sold at an average price of $56.76, for a total transaction of $7,272,488.52. Following the completion of the sale, the chief executive officer directly owned 160,215 shares of the company’s stock, valued at approximately $9,093,803.40. The trade was a 44.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Oluyemi Okupe sold 23,107 shares of the firm’s stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $47.25, for a total value of $1,091,805.75. Following the sale, the chief financial officer owned 63,222 shares in the company, valued at $2,987,239.50. The trade was a 26.77% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 737,704 shares of company stock valued at $40,644,035. 13.71% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently bought and sold shares of the stock. Farallon Capital Management LLC lifted its holdings in Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock worth $202,556,000 after buying an additional 8,364,000 shares during the period. Renaissance Technologies LLC increased its stake in shares of Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock valued at $168,079,000 after buying an additional 1,562,302 shares during the period. Geode Capital Management LLC raised its holdings in shares of Hims & Hers Health by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company’s stock valued at $104,724,000 after acquiring an additional 40,447 shares in the last quarter. Northern Trust Corp boosted its holdings in Hims & Hers Health by 19.5% in the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock valued at $71,969,000 after acquiring an additional 397,310 shares in the last quarter. Finally, Yong Rong HK Asset Management Ltd increased its position in Hims & Hers Health by 41.2% during the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock valued at $70,920,000 after purchasing an additional 700,100 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.